Critically ill Guillain Barre' syndrome.
Among the 153 patients fulfilling NINDS criteria for Guillain Barre' Syndrome (GBS) seen over 5.5 yrs, there were 47 (M:F 38.9) critically ill patients (age range 4 to 60 years). Antecedent event was recorded in 25 patients and the peak deficit was attained over a mean period of 9.5 days. Besides severe motor paralysis other salient features were: bulbar paralysis--42, sensory symptoms or signs--21, dysautonomia 31 and requirement for ventilatory assistance 45. CSF protein was raised in 63% cases. All the 17 patients who underwent electromyography had abnormalities of nerve conduction paramentes. Mean stay on the ventilator was 29.6 days and was not influenced by corticosteroid. Complications were frequent: pulmonary and urinary tract infection, dysautonomia, electrolyte disturbances, haemetmesis, bleeding from tracheostomy site and hepatic and renal failure. Mortality in steroids treated group (13/27) and the conservatively managed group (5/20) did not differ significantly. No discriminant factor emerged between survivors and non-survivors. Age and sex of the patients, presence of antecedent event, onset to peak interval and CSF protein level did not predict the need for ventilatory assistance, although these patients at admission had more frequent weakness of facial, bulbar, trunk, neck and proximal muscles of upper limbs and autonomic disturbances. Course of GBS remains unpredictable at the onset of the disease, warrants close supervision and meticulous supportive care and remains a therapeutic challenge.
Taly
A B
AB
Department of Neurology, National Institute of Mental Health & Neuro Sciences (NIMHANS), Bangalore.
Gupta
S K
SK
Vasanth
A
A
Suresh
T G
TG
Rao
U
U
Nagaraja
D
D
Swamy
H S
HS
Rao
S
S
Subbakrishna
D K
DK
D000293:Adolescent; D000328:Adult; D001342:Autonomic Nervous System Diseases / Q000150:complications; D002648:Child; D002675:Child, Preschool; D003422:Critical Care; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011129:Polyradiculoneuropathy / Q000150:complications / Q000401:mortality / Q000628:therapy*; D012121:Respiration, Artificial; D016019:Survival Analysis